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Abstract  
Skeletal metastasis of breast cancer is associated with a poor prognosis and significant morbidity. 
Investigations in other solid tumors have revealed an impairment in hematopoietic function upon 
bone marrow invasion. However, the interaction between disseminated breast cancer cells and the 
bone marrow microenvironment which harbors them has not been addressed comprehensively. 
Employing advanced co-culture assays, proteomic studies, organotypic models as well as in vivo 
xenotransplant models, we define the consequences of this interaction on the the stromal 
compartment of bone marrow, affected molecular pathways and subsequent effects on the 
hematopoietic stem and progenitor cells (HSPCs). The results showed a basic fibroblast growth 
factor (bFGF)-mediated, synergistic increase in proliferation of breast cancer cells and 
mesenchymal stromal cells (MSCs) in co-culture. The stromal induction was associated with 
elevated phosphoinositide-3 kinase (PI3K) signaling in the stroma, which coupled with elevated  
bFGF levels resulted in increased migration of breast cancer cells towards the MSCs. The 
perturbed cytokine profile in the stroma led to reduction in the osteogenic differentiation of MSCs 
via downregulation of platelet-derived growth factor-BB (PDGF-BB). Long term co-cultures of 
breast cancer cells, HSPCs, MSCs and the in vivo studies in NSG mice showed a reduced support 
for HSPCs in the altered niche. The resultant non-conducive phenotype of the niche for HSPC 
support emphasizes the importance of the affected molecular pathways in the stroma as clinical 
targets. These findings can be a platform for further development of therapeutic strategies aiming 
at the blockade of bone marrow support to disseminated breast cancer cells. 
 
Introduction 
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Breast cancer metastasis compounds the limitations of existing therapeutic modalities. Metastasis 
to other sites also increases the likelihood of tumor relapse [1,2]. Breast cancer cells usually 
metastasize to lung, brain, liver, spleen and bone [3-5]. Bone metastases have also been shown to 
cause skeletal comorbidities which adversely affect patient survival [4,6]. Disseminated tumor 
cells (DTC) have been observed in the bone marrow already at the time of initial diagnosis. 
However, the pathophysiological relevance of early bone marrow invasion by DTCs and its 
consequences on the bone marrow microenvironment have not been addressed comprehensively. 
Bone marrow is an anatomical region in the bone which comprises the niche for HSPCs [7-9]. The 
major components of the niche are the mesenchymal stromal cells and their differentiated 
counterparts, extracellular matrix (ECM) and morphogens which in a concerted manner maintain 
the stemness properties of the niche. Alterations in the marrow compartments have been shown to 
affect quiescence, self-renewal and survival of HSPCs [10,11]. Due to the stemness properties, the 
niche components may also become an unwitting target for neoplastic remodeling. 
It has been shown that skeletal metastasis of solid tumors like that of the prostate disrupt steady 
state hematopoiesis by reducing HSPC engraftment in the bone marrow and by driving the blood 
progenitor cells towards terminal differentiation [12]. We have also recently shown that breast 
cancer cells impaired transwell migration of HSPCs towards MSCs via downregulation of stromal 
derived factor-1 (SDF-1) and caused an increase in circulating clonogenic progenitors in breast 
cancer patients [13]. A perturbation in steady state hematopoiesis can be speculated to be 
dependent upon DTC mediated interference in HSPC-stroma interaction.  
In this context, our studies delineate the neoplastic remodeling of bone marrow components and 
the signaling pathways upon interaction with the invading breast cancer cells. Furthermore, our 
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work shows that alteration in the niche structure by invading breast cancer cells can lead to reduced 
support for the endogenous HSPCs. 
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Materials and Methods 
Cell culture of breast cancer cell lines and MCF-10A cells 
MDA-MB231 and MCF-7 breast cancer cell lines were obtained from the German Collection of 
Microorganisms and Cell Cultures (DSMZ, Braunschweig, Germany) and maintained in 
Dulbecco’s modified Eagle’s medium (DMEM) GlutaMax (Invitrogen, Germany) supplemented 
with 10% fetal calf serum (FCS; Biochrom, Berlin, Germany). Non-tumorigenic breast epithelial 
cell line- MCF-10A was obtained from ATCC (LGC Standards GmbH, Wessel, Germany).  MCF-
10A cell line was cultured in DMEM/F12 (Gibco Life Technologies, Darmstadt, Germany) 
supplemented with 5% horse serum (Invitrogen), 20ng/mL EGF (Peprotech, Hamburg, Germany), 
0.5μg/mL hydrocortisone, 10μg/mL insulin and 100ng/mL cholera toxin (all these components 
were from Sigma-Aldrich, Steinheim, Germany). The cell lines were cultured at 37oC and 5%CO2.  
In the co-culture studies, the cell lines were maintained in DMEM+10%FCS to avoid interference 
by additional medium components. 
Isolation and culture of primary human MSC 
Primary human bone marrow derived MSC were collected from bone marrow aspirates from 
healthy donors after informed consent and approval by the local ethics committee. Mononuclear 
cells were collected using a Ficoll gradient and cultured at 37oC and 5%CO2 in DMEM 
supplemented with 10% FCS. After 24 hours, non–adherent cells were removed and adherent cells 
were expanded. The immunophenotype of all primary MSC was analyzed by flow cytometry 
(CD166+, CD105+, CD90+, CD73+, CD34- and CD45-). Primary MSC from passages 2-3 were 
used for the experiments. 
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Isolation of CD34+ cells from leukapheresis samples 
CD34+ cells were isolated from leukapheresis samples of healthy donors after taking informed 
consent in accordance with research protocol approved by the local institutional review board.  
CD34+ cells were isolated from leukapheresis samples of healthy donors treated with 7.5μg/kg 
granulocyte-stimulating factor subcutaneously for 5 consecutive days. HSPCs were isolated using 
CD34 antibody-conjugated magnetic beads, according to manufacturer’s instructions (Miltenyi 
Biotec, Bergisch Gladbach, Germany). The purity of the isolated CD34+ population was confirmed 
to be 90-97% by flow cytometry.   
Generation of breast cancer cell line with constitutive EGFP expression    
The MDA-MB231 cell line was transfected with pEGFP-N1 (Clontech, USA) using 
Lipofetcamine 2000 (Invitrogen), selected by Geneticin (G418) (Sigma,Germany) and sorted by 
flow cytometry (BD Aria II) to obtain >90% EGFP expression. 
Proliferation assays 
5x104 MSCs were seeded in the 6-well plates, 1x104 breast cancer cells and MCF-10A cells were 
seeded in the transwell inserts (pore size: 1μm) (Millipore, Germany). The co-cultures were 
maintained for 7 days under hypoxic culture conditions (0.5% Oxygen) (Biospherix, USA). The 
cells were harvested and counted on day 1, 3, 5 and 7 using a hemocytometer. In the FGFR 
blocking studies, 0.5ng/ml of rhbFGF (Peprotech, USA), 2.5μM of SU5402 (Millipore, Germany) 
were added to the co-cultures. In the PI3K blocking studies, 0.4μM of LY294002 (Cell Signaling 
Technologies, Germany) was added to the co-cultures. The cells were harvested and counted on 
day 5. The co-cultures were maintained under hypoxic culture conditions. 
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Cytokine Array 
Human Cytokine Arrays VI and VII (Ray Biotech Inc, Norcross, GA) consisting of 120 different 
cytokine antibodies spotted in duplicate onto two membranes were used. Supernatants from breast 
cancer cells-MSC co-cultures and MSC monocultures (day 5) from three independent experiments 
were pooled separately and used in the array. The array was performed according to 
manufacturer’s instructions. The cytokine signals were detected via Luminescent Image Analyzer-
3000 (LAS-3000 Bioimager) (Fuji Film, Japan) and analyzed using Image Gauge version 4.23. 
The intensity of each cytokine spot was measured on the basis of gray-scale levels. The net 
intensity level was determined by subtracting the average level of spot intensities of blank from 
the measured intensity levels for each spot. The intensity level of six positive controls was used to 
normalize the results from different membranes. The intensity for each cytokine was then averaged 
over duplicated spot signals. The results were expressed as fold change in intensity levels of co-
cultures over intensity level of the respective cytokine in MSC monocultures. 
Western blot analysis 
1.5x105 MSCs were seeded in the 6-well plates, 3x104 breast cancer cells and MCF-10A cells were 
seeded in the transwell inserts. The co-cultures were maintained for 24 hours under hypoxic culture 
conditions. Whole-cell lysates were obtained using Mammalian Protein Extraction Reagent 
supplemented with protease inhibitor (ThermoScientific, Germany) according to manufacturer’s 
instructions. The proteins transferred on nitrocellulose membranes were blocked and incubated 
overnight with anti-AKT, dilution-1:1000) (CST,Germany), anti-Phospho-AKT, dilution-1:2000 
(CST, Germany) and human anti-GAPDH (Abcam, Germany) antibodies.  
 9 
Goat anti-rabbit-horseradish peroxidase (HRP) (GE Healthcare, Germany) and Goat anti-mouse-
HRP (Thermoscientific, Germany) were used as secondary antibodies. Western blots were 
visualized with ECL Primer Western blotting detection reagent (Amersham) on LAS 3000. 
GAPDH, served as loading control. 
Transwell migration assays 
MDA-MB231 cells (0.3x105) were seeded in 8-μm Transwell inserts (CoStar, Germany), in 
DMEM without FCS and placed in 24-well plates with a confluent layer of MSCs supplemented 
with supernatants from tumor-MSC co-cultures or DMEM+10% FCS. In FGFR blocking studies, 
the MSC layer was supplemented with tumor-MSC supernatants along with 2.5μM SU5402. In 
the PI3K inhibition studies, the MSC layer was supplemented with tumor-MSC supernatants along 
with 0.4μM LY290042. At the end of 5 hours under hypoxic culture conditions, the inserts were 
removed, fixed with 4% formaldehyde and stained with Crystal Violet (Merck Millipore, 
Germany). The inserts were then incubated with 0.25% triton-X-100 (Merck, Germany) and 
optical density values (OD) were measured using the Anthos plate reader at 620nm. The difference 
in OD values was measured as change in migration levels and was expressed as fold change over 
the migration of MDA-MB231 cells towards a well without any supernatants (blank). 
Osteogenic differentiation 
MSCs were seeded at a density of 5x103/cm2 and cultured in DMEM with 10% FCS until cells 
reached 70% confluence (3 days).The growth media used to induce osteogenic differentiation was 
prepared as described before [14]. The breast cancer cells and MCF-10A cells were seeded in the 
transwell inserts.  
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Alkaline phosphatase (ALP) activity in MSCs was measured after 12 days in culture with 
osteogenic medium under normoxic culture conditions (20% oxygen) as described before [14]. 
Mineralization was evaluated with Von Kossa staining after 14 days in culture with osteogenic 
medium as described before [14]. In the rescue experiments, 20ng/mL rhPDGF-BB (Invitrogen, 
Germany) was added to the co-cultures. 
Osteogenic differentiation in three dimensional (3D) co-cultures 
Matrix metalloproteinase (MMP)-cleavable star-polyethylene glycol (PEG)-heparin hydrogels 
were prepared as described previously [15,16]. For MSCs, the heparin-maleimide fraction of the 
hydrogel was first functionalized with 2 mol of the adhesion peptide RGD-SP (H2N-
GCWGGRGDSP-CONH2; MW 990; synthesized within our laboratory) per mole of heparin and 
vortexed thoroughly. MSCs at a density of 1.2x106/mL were seeded into MMP-cleavable star-
PEG-heparin hydrogels at a crosslinking degree of ϒ1.25 (molar ratio of star-PEG to heparin-
maleimide). In the PDGF-BB rescue experiments, 5μg/mL of rhPDF-BB was added to the heparin-
maleimide solution. MSCs were afterwards seeded at a density of 6×105/mL into the heparin 
fraction. The heparin-maleimide-cell suspension was mixed with the star-PEG solution (1:1 
volume ratio) to create a ϒ1.25, 3000 Pa (storage modulus) hydrogel. The MSCs were maintained 
in DMEM+10% FCS until they reached 70% confluence (3 days). At the end of 3 days, the breast 
cancer cells and MCF-10A cells at a density of 1.5×105/mL were seeded separately into non-
functionalized star-PEG-heparin hydrogels at a crosslinking degree of ϒ1. Subsequently, the gel 
compartments of the pre-embedded MSCs, breast cancer cells or MCF-10A cells were then 
maintained together in osteogenic differentiation medium for 12 days under normoxic culture 
conditions (in one well).  
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After 12 days, the hydrogels with MSCs were harvested using 2mg/mL collagenase (SERVA, 
Heidelberg, Germany), centrifuged and the pellets were used for ALP analysis.  
Cobblestone area-forming cell (CAFC) assay  
5x103 freshly isolated CD34+ cells were seeded on a confluent layer of MSCs (seeded at 
1.6x104/cm2) in a 6-well plate and maintained for four weeks in Myelocult H5100 medium (Stem 
Cell Technology), supplemented with 10-6M hydrocortisone (Sigma-Aldrich, St. Louis, MO). Half 
medium exchanges were made weekly. 3x102 breast cancer cells and MCF-10A cells were seeded 
in the transwell inserts at the end of the third week. The cobblestone area scoring was done at the 
end of third and fourth week. Cobblestone areas were counted using an inverted microscope 
(Axiovert 25; Carl Zeiss, Jena, Germany) and counted as colonies when at least 5 cells formed a 
colony beneath the stromal layer. 
Breast cancer cells, MCF-10A and HSPC transplantation experiments 
Animal studies were conducted in accordance with the guidelines of the Animal Care and Use 
Committee of the Medical Faculty at the University of Dresden and had been approved by the 
relevant local authorities. Cell suspensions of breast cancer cells and MCF-10A cells containing 
0.75x106 cells in PBS mixed with matrigel in 1:1 ratio were injected subcutaneously in the right 
flank of the anaesthetized (Ketamine/Xylazine-100mg/kg and 10mg/kg body weight respectively) 
female,  NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice. 1 week later, after the development of 
tumor nodules, mice received 100 cGy whole-body irradiation (WBI) using a Yxlon MaxiShot X-
ray irradiator (Yxlon), between 4h and 24 h before human HSPC injection. Cell suspensions 
containing 1x105 CD34+ HSPCs in 100 µl PBS+5% FCS were injected intravenously into the retro-
orbital venous plexus.  
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For the first three weeks after transplantation, water was supplemented with neomycin 
(0.29g/250mL) (Sigma, Germany). Tumor size (maximal and orthogonal diameters) and weight of 
the animals was measured on a weekly basis (data not shown). Mice were sacrificed five weeks 
after HSPC transplantation. Hind legs were prepared as single-cell suspension for further analysis 
as described previously [17]. Viability and cell count were determined using the MACSQuant 
Analyzer. All antibodies against human or mouse lymphocytes were used at appropriate dilutions 
(antibody list in supplemental data section), as determined by previous titration. Doublet 
discrimination was carried out and non-viable cells were excluded by 4,6 diamidino-2-
phenylindole (DAPI) staining (Sigma). All measurements were performed on BD LSR II (BD 
Biosciences). Data analysis was done using FlowJo software (Tree Star). For studies with EGFP-
expressing-MDA-MB231 cells, the same cell dose and irradiation dose were used as mentioned 
above. The mice were analyzed six weeks after tumor cell transplantation. The femur was flushed 
and the mice transplanted with MDA-MB231-EGFP cells were stained with human anti-CD44-
APC (Immunotools), PE-conjugated anti-mouse CD45. The MDA-MB231 cells were detected on 
basis of CD44 and EGFP co-expression. Doublet discrimination was performed and non-viable 
cells were excluded using using Propidium iodide (PI). The measurements were performed on 
MACSQuant and data was analyzed using FlowJo software (Tree Star). 
 Statistics 
Data were analyzed using Student’s t-test using GraphPadPrism5. Data is presented from 
experiments performed with MSCs and HSPCs derived from at least 3 healthy donors, unless 
mentioned otherwise. All results are reported as means ± standard deviation. Statistical 
significance was established as p<0.05(*), p<0.001(**), p<0.0001(***). 
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Results 
Breast cancer cells and MSCs cause a synergistic increase in the proliferation of both cell 
types. 
A non-contact culture set up was used to study the proliferation of MSCs and breast cancer cells 
over a period of 7 days at-day 1, 3, 5 and 7. 1x104 breast cancer cells were seeded in the transwell 
inserts and 5x104 MSCs were seeded in the wells below. MSCs in co-culture with breast cancer 
cells showed significant increase in their proliferation at day 5 and 7 as compared to MSC 
monocultures (Figure 1A,B). However, the non-tumorigenic cell line MCF-10A did not cause any 
significant difference in the MSC proliferation at any time point (Supplemental figure S1). In 
parallel, there was also, an increase in the proliferation of breast cancer cells in co-culture with the 
MSCs as compared to breast cancer cells’ monoculture (MDA-MB231 cells at day 5 and 7, MCF-
7 cells at day 3 and 5) (Figure 1C,D). Since the co-culture was non-contact, we speculated a 
humoral interaction between the breast cancer cells and MSCs. 
Breast cancer cells cause a perturbation in the cytokine profile of MSCs. 
Since MDA-MB231 and MCF-7-MSC co-cultures showed an increase in the MSC proliferation 
on day 5, the supernatants from the co-cultures and MSC monocultures were used for the cytokine 
array. The difference in cytokine levels in co-cultures were expressed as fold change over the 
expression signals in MSC monocultures. A fold change of >1.40 and <0.71 was considered to be 
upregulated and downregulated respectively. 27 out of the 120 cytokines showed similar trends in 
regulation by both the breast cancer cell lines (Figure 2A,B, supplemental figure S2A,B and 
supplemental table 1).  
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Furthermore, 24 cytokines were differentially regulated exclusively by MDA-MB231 cells and 7 
cytokines were differentially regulated exclusively by MCF-7 cells (Fig.2C). The array showed 
alteration in the levels of growth factors and pro-inflammatory cytokines in MSCs upon co-culture 
with MDA-MB231 and MCF-7 cells (bFGF-2.2 and 1.60 fold upregulation; PDGF-BB- 0.55 and 
0.50 fold downregulation and Tumor necrosis factor-alpha-TNF-α-0.52 and 0.56 fold 
downregulation in MDA-MB231 and MCF-7-MSC co-cultures respectively). Differential 
regulation of critical growth factors can regulate the MSC fate and breast cancer cell survival. 
bFGF and PDGF-BB have been shown to play a permissive role in promoting hematological 
malignancies and solid tumors along with regulating the self-renewal of bone marrow stroma and 
bone turnover [18-24]. Therefore we chose to dissect their roles in the tumor-bone marrow stroma 
crosstalk.  
Elevated bFGF levels regulate the increase in proliferation of breast cancer cells and MSCs 
in co-culture. 
bFGF was one of the growth factors that was upregulated in the tumor-MSC co-cultures. Since 
bFGF has been shown to regulate MSC proliferation as well as tumor survival [18-22], we 
investigated the role of bFGF in the synergistic increase in proliferation of both cell types. The 
breast cancer cells-MSC co-cultures were incubated with FGFR inhibitor (SU5402) and the effects 
on proliferation of MSCs, breast cancer cells were studied on day 5. Addition of the inhibitor 
reversed the increase in proliferation of MSCs in co-cultures to MSC monocultures (Figure 3A). 
Additionally, incubation with the inhibitor also reversed the increase in proliferation of breast 
cancer cells in co-cultures to breast cancer cells’ monocultures (Figure 3B,C).  
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However, incubation with SU5402  did not cause any significant changes in the proliferation of  
MSC or breast cancer cell monocultures as compared to untreated cells (Supplemental figure S3A-
C). Furthermore, we investigated if the downstream phosphorylated protein pathways would also 
play a role in the breast cancer cells-MSC interaction. 
Activated PI3K signaling in MSCs regulates proliferation of MSCs, breast cancer cells and 
transwell migration of MDA-MB231 cells towards MSCs. 
Breast cancer cells in MSC-co-cultures caused an increase in the phosphorylated AKT (pAKT) 
levels in MSCs. However, there was no detectable increase in pAKT levels in MSCs in MCF-10A-
co-cultures (Figure 4A). The breast cancer cell-MSC co-cultures were further incubated with PI3K 
inhibitor (LY294002) to study the role of PI3K signaling in breast cancer cell-MSC proliferation. 
Addition of the inhibitor reversed the increase in proliferation of MSCs in co-cultures to MSC 
monocultures (Figure 4B). Additionally, incubation with the inhibitor also reversed the increase 
in proliferation of breast cancer cells in co-cultures to breast cancer cells’ monocultures (Figure 
4C,D). However, incubation with LY294002  did not cause any significant changes in the 
proliferation of  MSC or breast cancer cell monocultures as compared to untreated cells 
(Supplemental figure S4A-C). Furthermore, we also observed an increase in the transwell 
migration of MDA-MB231 cells towards MSCs incubated with supernatants from breast cancer 
cells-MSC co-cultures (previously shown to have elevated bFGF levels) as compared to controls 
(Figure 4E). However, the supplementation of breast cancer cells-MSC supernatants with SU5402 
and LY294002 separately, partially aborted the increase in transwell migration of MDA-MB231 
cells towards MSCs (Figure 4E).  
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Thus, the breast cancer cells’ mediated alteration in bFGF and phosphoprotein levels interfered 
with the MSC proliferation and breast cancer cell migration to the bone marrow. We further  
investigated  the effects of these incoming tumor cells on the potential of MSCs to differentiate to 
bone forming cells of the niche-osteoblasts. 
Breast cancer cells reduce the osteogenic differentiation of MSCs via downregulation of 
PDGF-BB. 
The MSCs were co-cultured with breast cancer cells and MCF-10A cells in osteogenic 
differentiation medium for 12 days. Breast cancer cells and not MCF-10A cells caused a reduction 
in ALP levels in MSCs induced with osteogenic differentiation medium (Figure 5A). Von Kossa 
staining to study mineralization nodules also showed reduction in mineralization nodules in MSCs 
co-cultured with breast cancer cells (Figure 5B). The cytokine array had shown downregulation in 
PDGF-BB levels in MSCs co-cultured with breast cancer cells. Previous work has shown that 
PDGF-BB regulates bone turnover and augments bone formation [24,25]. Therefore, we 
investigated the role of PDGF-BB in breast cancer cell mediated reduction in osteogenic 
differentiation of MSCs. Exogenous supplementation of rhPDGF-BB to breast cancer-MSC co-
cultures caused a significant increase in  ALP levels as compared to controls (Figure 5A). There 
was also an increase in the mineralization nodules upon supplementation with rhPDGF-BB (Figure 
5B). We extended these studies to 3D co-cultures within star-PEG-heparin hydrogels. The MSCs, 
breast cancer cells and MCF-10A cells were encapsulated separately in hydrogels. Then the MSCs 
were co-cultured with breast cancer cells and MCF-10A cells in one well in order to mimic the 
individual microenvironment of the particular cell type but allowing for paracrine signaling 
through soluble morphogens (Figure 5C). Breast cancer cells caused a significant reduction in ALP 
levels of MSCs as compared to controls (Figure 5D).  
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Preloading of the MSC-hydrogel compartment with the heparin binding rhPDGF-BB could rescue 
the breast cancer cells’ mediated impairment in osteogenic differentiation of MSCs (Figure 5D). 
Breast cancer cells reduce the cobblestone areas in HSPC-MSC co-cultures and HSPC 
engraftment in mice.  
We studied the effects of breast cancer cells on stromal–HSPC interaction via CAFC assay. The 
CD34+ HSPC suspension were seeded on the sub-confluent MSC layer. Cobblestone areas were 
allowed to establish for 3 weeks. At the end of 3 weeks, the breast cancer cells and MCF-10A were 
co-cultured with HSPC-MSC via the non-contact set up. There was a significant reduction in 
number of cobblestone areas 1 week after the introduction of breast cancer cells and not by MCF-
10A cells (Figure 6A). We further extended the studies to a NSG mouse model, where we studied 
the effects of breast cancer cells on HSPC engraftment. The breast cancer cells and MCF-10A cells 
were transplanted subcutaneously mixed with matrigel. The CD34+ HSPCs were transplanted 
intravenously 1 week after the development of tumor nodules. MDA-MB231 cells caused a 
significant reduction in the human CD45+ chimerism and HSPC chimerism (%hCD34+hCD45+ of 
CD45+ cells) in the bone marrow 5 weeks after HSPC transplant (Figure 6B,C). Furthermore, we 
also detected MDA-MB231 cells in the bone marrow 6 weeks after tumor cell transplantation by 
CD44 and EGFP co-expression (Figure 6D, supplemental figure S5), which further suggest a 
tumor cell mediated impairment in HSPC support. 
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Discussion 
Understanding the modulation of bone marrow microenvironment by metastatic breast cancer cells 
is important to identify clinical targets which can prevent tumor relapse and skeletal comorbidities. 
Our work identified the differentially regulated growth factors and downstream signaling pathways 
that caused interference in the stromal compartments.  This remodeling of the HSPC niche by the 
disseminated breast cancer cells eventually led to reduced support for the native HSPCs (Figure 
7). 
Hypoxia is a critical factor in the bone marrow mediated regulation of HSPC fate. The bone 
marrow microenvironment has been reported to be hypoxic [26,27]. Studies have reported the 
oxygen tension in the marrow in the range of <0.5% in endosteal bone compartments to 6% in 
sinusoidal cavities [28-30]. In this context, we used hypoxic culture conditions for most part of 
our studies to partially mimic the oxygen tension in the niche. We observed a bFGF mediated 
increase in the proliferation of breast cancer cells and MSCs in co-culture. It can be speculated 
that the paracrine cues from the activated stroma might facilitate support for the malignant tumor 
phenotype [31,32]. Though stromal involvement in promoting prostate, breast cancer metastasis 
and hematological malignancies like multiple myeloma has been documented [32-35], it was 
interesting to discover the tumor cell induced activation of the stroma via increased proliferation. 
A bFGF mediated bidirectional interaction between multiple myeloma cells and bone marrow 
stroma has been reported to confer drug resistance to cell death while promoting proliferation of 
multiple myeloma cells [36]. Additionally, elevated levels of bFGF have been detected in bone 
marrow samples of multiple myeloma patients [37,38]. Constitutive activation of FGF signaling 
has also been implicated in fostering tumorigenesis across solid tumors, leukemias and inducing 
migration of MDA-MB231 cells [19,39,40].  
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At the same time, bFGF is known to critically regulate self-renewal and proliferation of bone 
marrow derived mesenchymal stromal cells [20-22]. Therefore, the activation of the bFGF 
pathway in breast cancer-bone marrow crosstalk can be speculated to foster a tumorigenic priming 
of the niche to harbor and support invading tumor cells.  
Further investigation of the downstream phosphorylated protein pathways revealed an increase in 
the levels of pAKT in the MSCs in co-culture with tumor cells. Investigations on other downstream 
phosphorylated protein pathways (pERK, pSAPK/JNK) showed that there was no detectable 
increase in pERK and pSAPK/JNK levels in MSCs in co-culture with breast cancer cells (data not 
shown). Activated PI3K signaling is associated with critical roles in regulating MSC fate, survival, 
proliferation and cytokine production [41]. The elevated bFGF levels as shown in the cytokine 
array, coupled with cessation of synergistic increase in proliferation of MSCs and breast cancer 
cells upon incubation of co-cultures with FGFR and PI3K inhibitors suggest that the bFGF and 
phosphoprotein loop might be activated in the breast cancer cells-bone marrow stroma dialogue. 
Tumor-cell mediated differential regulation of other phosphorylated protein pathways in the MSC 
proteome might also play a critical role in the tumor-MSC crosstalk. We speculate that inhibiting 
this interaction might impede tumor induced MSC expansion, breast cancer metastasis and 
development of a tumor-facilitating stroma.  
Following the tumor mediated stromal induction, we investigated the consequences of metastatic 
tumor cells on the bone forming cells of the niche. Osteoblast-HSPC interaction has been shown 
to regulate HSPC self-renewal and differentiation [10,42]. Groen et al also reported the role of a 
humanized, osteoblast regulated microenvironment in multiple myeloma [43].  
Interestingly, a PDGF-BB mediated impairment in osteogenic differentiation revealed a 
differentiation block in the stromal properties of MSCs. rhPDGF-BB has been shown to augment 
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bone formation in a rat model [25]. PDGF-BB depleted osteoclasts in mice were shown to have 
reduced bone mass and reduced PDGF-BB levels in the bone marrow [24]. Recent studies have 
highlighted the physiological and temporal mimicking of tumor cells and the bone marrow 
microenvironment in organotypic cell culture models [16,44-45]. The phenotype in 3D co-cultures 
could further implicate the involvement of perturbed PDGF-BB signaling in patients with breast 
cancer skeletal metastasis. Hematological malignancies have also been shown to reduce osteoblast 
numbers and function resulting in bone loss and hematopoietic defects [46,47]. Thus we speculate 
that a breast cancer cell mediated reduction in osteoblasts can result in reduced support for the 
native HSPCs, thereby developing a non-conducive niche for the native residents. 
The in vivo findings demonstrate a tumor cell mediated interference in short-term engraftment of 
HSPCs. The reduced engraftment or impaired support for HSPCs could arise due to a competition 
for the niche hot spots as shown in our recent work on competition between breast cancer cells and 
HSPCs for binding to MSCs (manuscript under revison). This can also arise due to the stromal 
impairment mediated via paracrine interactions as demonstrated in the in vitro findings. Preclinical 
studies with patient derived MSCs are needed to confirm the clinical relevance of our findings and 
to develop candidate therapeutic approaches interfering with relevant pathways in DTCs or MSCs 
in the bone marrow with the aim of reducing the induction of stromal alterations.  
 
Further studies using organoid culture models and appropriate humanized mouse models could 
decipher the roles of other differentially regulated growth factors and pro-inflammatory cytokines 
in the tumorigenic priming of the niche. In addition to our findings, we speculate that a global 
analysis of tumor-niche crosstalk, based on the variations in metastatic behavior of breast 
carcinoma subtypes might unravel further differences in tumor-host interactions, which could aid 
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the development of subtype specific therapeutic paradigms. Clinical trials will be needed to 
unravel whether therapies targeting the interference with the tumor environment early during 
disease will help to improve the outcome of patients with high-risk disease. 
 
Summary 
Disseminated breast cancer cells in bone marrow have been described by the time of primary 
diagnosis. The spread to the marrow and niche hijacking may serve as seed and soil for subsequent 
skeletal/visceral progression. Therefore, delineating the DTC-bone marrow crosstalk is clinically 
relevant to interfere with niche based tumor support and recurrence. We investigated if DTCs 
would cause a neoplastic transformation of the niche components and whether these alterations 
would affect the native residents-HSPCs. Identification of the DTC mediated stromal perturbations 
which adversely affected HSPC support, offer a novel therapeutic avenue for preventing DTC 
refuge in the HSPC niche. 
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Figure legends : 
Figure 1:  Breast cancer cells and MSCs cause a synergistic increase in the proliferation of both 
cell types. 
A,B) 1x104 breast cancer cells (MDA-MB231, MCF-7) and 5x104 MSCs were seeded in the inserts 
and well below respectively. The proliferation of MSCs was monitored over day 1, 3, 5, and 7. 
C,D) The proliferation of breast cancer cells was monitored over day 1, 3, 5, and 7 (n=3 for MDA-
MB231-MSC co-cultures and n=4 for MCF-7-MSC co-cultures). Bars represent mean ± SD for all 
independent experiments, P<0.05(*), P<0.001(**), P<0.0001(***). 
Figure 2: Breast cancer cells cause a perturbation in the cytokine profile of MSCs. 
A,B) Scatter plot showing mean spot intensities of cytokines (represented by a dot) in MSC 
monocultures and in MSCs in co-culture with breast cancer cell lines. Data from 27 cytokines that 
showed similar trends in regulation by both the breast cancer cell lines. bFGF (marked as red spot) 
and PDGF-BB (marked as green spot) were amongst the upregulated and downregulated cytokines 
respectively. Data from 120 cytokines shown in Supplemental figure S2A,B). C) Venn diagram 
showing the pattern of differential regulation by the breast cancer cell lines. 
Figure 3: Elevated bFGF levels regulate the increase in proliferation of breast cancer cells and 
MSCs in co-culture. 
A) The breast cancer cells-MSC co-cultures were supplemented with FGFR inhibitor and 
maintained for 5 days. The proliferation of MSCs in co-cultures was compared with MSC 
monocultures (n=3 for breast cancer cells-MSC co-cultures, n=6 for MSC monocultures).  
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B,C) The proliferation of breast cancer cells in co-cultures was compared with breast cancer cells’ 
monocultures (n=3). Bars represent mean ± SD for all independent experiments, P<0.05(*), 
P<0.001(**), P<0.0001(***). 
Figure 4: Activated PI3K signaling in MSCs regulates proliferation of MSCs, breast cancer cells 
and transwell migration of MDA-MB231 cells towards MSCs. 
Representative western blot showing pAKT levels in MSCs in co-culture with breast cancer cells, 
MCF-10A cells and MSC monocultures at 24 hours (n=3). B) The breast cancer cells–MSC co-
cultures were supplemented with PI3K inhibitor and maintained for 5 days. The proliferation of 
MSCs in breast cancer cells-MSC co-cultures was compared with MSC monocultures (n=3 for 
breast cancer cells-MSC co-cultures, n=6 for MSC monocultures). C,D) The proliferation of breast 
cancer cells in breast cancer cells-MSC co-cultures was compared with breast cancer cells’ 
monocultures (n=3). E) The transwell migration of MDA-MB231 cells towards MSCs 
supplemented with breast cancer cells-MSC supernatants with (n=4) and without FGFR, PI3K 
inhibitors (n=3). Bars represent mean ± SD for all independent experiments, P<0.05(*), 
P<0.001(**), P<0.0001(***). 
Figure 5: Breast cancer cells reduce the osteogenic differentiation of MSCs via downregulation of 
PDGF-BB. 
Relative change in ALP levels of MSCs co-cultured with breast cancer cells and MCF-10A cells 
in osteogenic differentiation medium. The ALP values were normalized to MSC monocultures and 
differences with different conditions were expressed as fold change with respect to MSC 
monocultures (n=5 for MSC monocultures and co-cultures with MDA-MB231,MCF-7,MCF-10A 
cells, n=4 for MSCs+rhPDGF-BB and n=3 for rescue studies with rhPDGF-BB).  
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B) Representative image of Von Kossa staining of MSCs co-cultured with breast cancer cells, 
MCF-10A cells and also with rhPDGF-BB supplementation. The bright field images were acquired 
at 20x magnification. C) Schematic of the star-PEG-heparin hydrogel chemistry and the images of 
hydrogels containing breast cancer cells and MSCs. D) Relative change in ALP levels of MSCs 
co-cultured with breast cancer cells and MCF-10A cells in hydrogels. The ALP values were 
normalized to MSC monocultures and differences with different conditions were expressed as fold 
change with respect to MSC monocultures (n=8 for MSC monocultures and co-cultures with 
MDA-MB231, MCF-7, n=5 for MCF-10A cells, n=4 for MSCs+rhPDGF-BB and n=3 for rescue 
studies with rhPDGF-BB). Bars represent mean ± SD for all independent experiments, P<0.05(*), 
P<0.001(**), P<0.0001(***). 
Figure 6: Breast cancer cells reduce the cobblestone areas in HSPC-MSC co-cultures and HSPC 
engraftment in mice.  
A)The cobblestone areas were allowed to establish over a period of 3 weeks in the HSPC-MSC 
co-cultures. At the end of 3 weeks the number of cobblestone areas were scored and co-cultured 
further with breast cancer cells, MCF-10A cells for one week. At the end of the 4th week, the 
cobblestone areas were scored in respective conditions. B,C) Relative change in percent hCD45+ 
and HSPC chimerism in bone marrow of mice transplanted with breast cancer cells and MCF-10A 
cells. Each data point represents one transplanted mouse. The values were normalized to the 
chimerism in mice transplanted with HSPCs only and differences with different conditions were 
expressed as fold change with respect to mice transplanted with HSPCs only (Tx; n=2 independent 
transplantation experiments,4-5 mice per group. D) Representative FACS plot showing MDA-
MB231 cells in the bone marrow 6 weeks after transplantation. Data  shown from experiments 
with 3 mice. Bars represent mean ± SD, P<0.05(*), P<0.001(**), P<0.0001(***). 
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Figure 7: Model depicting the neoplastic transformation of the bone marrow microenvironment 
via the invading breast cancer cells. A bFGF mediated induction of the mesenchymal stromal cells 
coupled with activated PI3K signaling fosters a tumor supporting stroma in the bone marrow. 
Further block in the osteogenic differentiation of MSCs via downregulation of PDGF-BB alters 
the niche structure. The pro-tumorigenic stroma becomes non-conducive for HSPC support. 
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